|
1
|
Ileana EE, Wistuba II and Izzo JG: From
uniplex to multiplex molecular profiling in advanced non-small cell
lung carcinoma. Cancer J. 21:413–424. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al: Erlotinib versus standard
chemotherapy as first-line treatment for European patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): A multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yang JC, Wu YL, Schuler M, Sebastian M,
Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, et al:
Afatinib versus cisplatin-based chemotherapy for EGFR
mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6):
Analysis of overall survival data from two randomised, phase 3
trials. Lancet Oncol. 16:141–151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yu HA, Arcila ME, Rekhtman N, Sima CS,
Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M and Riely GJ:
Analysis of tumour specimens at the time of acquired resistance to
EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Clin Cancer Res. 19:2240–2247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sequist LV, Waltman BA, Dias-Santagata D,
Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger
S, Cosper AK, et al: Genotypic and histological evolution of lung
cancers acquiring resistance to EGFR inhibitors. Sci Transl Med.
3:75ra262011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pao W, Miller VA, Politi KA, Riely GJ,
Somwar R, Zakowski MF, Kris M and Varmus H: Acquired resistance of
lung adenocarcinomas to gefitinib or erlotinib is associated with a
second mutation in the EGFR kinase domain. PLoS Med. 2:e732005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Engelman JA, Zejnullahu K, Mitsudomi T,
Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen
J, et al: MET amplification leads to gefitinib resistance in lung
cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Furugen M, Uechi K, Hirai J, Aoyama H,
Saio M, Yoshimi N, Kinjo T, Miyagi K, Haranaga S, Higa F, et al: An
autopsy case of two distinct, acquired drug resistance mechanisms
in epidermal growth factor receptor-mutant lung adenocarcinoma:
Small cell carcinoma transformation and epidermal growth factor
receptor T790M mutation. Intern Med. 54:2491–2496. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Alì G, Bruno R, Giordano M, Prediletto I,
Marconi L, Zupo S, Fedeli F, Ribechini A, Chella A and Fontanini G:
Small-cell lung cancer transformation and the T790M mutation: A
case report of two acquired mechanisms of TKI resistance detected
in a tumor rebiopsy and plasma sample of EGFR-mutant lung
adenocarcinoma. Oncol Lett. 12:4009–4012. 2016.PubMed/NCBI
|
|
11
|
Peled N, Wynes MW, Ikeda N, Ohira T,
Yoshida K, Qian J, Ilouze M, Brenner R, Kato Y, Mascaux C and
Hirsch FR: Insulin-like growth factor-1 receptor (IGF-1R) as a
biomarker for resistance to the tyrosine kinase inhibitor gefitinib
in non-small cell lung cancer. Cell Oncol (Dordr). 36:277–288.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Thomson S, Buck E, Petti F, Griffin G,
Brown E, Ramnarine N, Iwata KK, Gibson N and Haley JD: Epithelial
to mesenchymal transition is a determinant of sensitivity of
non-small-cell lung carcinoma cell lines and xenografts to
epidermal growth factor receptor inhibition. Cancer Res.
65:9455–9462. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Scher KS, Saldivar JS, Fishbein M,
Marchevsky A and Reckamp KL: EGFR-mutated lung cancer with
T790M-acquired resistance in the brain and histologic
transformation in the lung. J Natl Compr Canc Netw. 11:1040–1044.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Levin PA, Mayer M, Hoskin S, Sailors J,
Oliver DH and Gerber DE: Histologic transformation from
adenocarcinoma to squamous cell carcinoma as a mechanism of
resistance to EGFR inhibition. J Thorac Oncol. 10:e86–e88. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jukna A, Montanari G, Mengoli MC, Cavazza
A, Covi M, Barbieri F, Bertolini F and Rossi G: Squamous cell
carcinoma ‘Transformation’ concurrent with secondary T790M mutation
in resistant EGFR-mutated adenocarcinomas. J Thorac Oncol.
11:e49–e51. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Longo L, Mengoli MC, Bertolini F, Bettelli
S, Manfredini S and Rossi G: Synchronous occurrence of squamous
cell carcinoma ‘transformation’ and EGFR exon 20 S768I mutation as
a novel mechanism of resistance in EGFR-mutated lung
adenocarcinoma. Lung Cancer. 103:24–26. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jamal-Hanjani M, Quezada SA, Larkin J and
Swanton C: Translational implications of tumor heterogeneity. Clin
Cancer Res. 21:1258–1266. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Piotrowska Z and Sequist LV: Epidermal
growth factor receptor-mutant lung cancer: New drugs, New
resistance mechanisms, and future treatment options. Cancer J.
21:371–347. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li Y, Song Z, Jin Y, Tang Z, Kang J and Ma
X: Novel selective and potent EGFR inhibitor that overcomes
T790M-Mediated resistance in non-small cell lung cancer. Molecules.
21:pii: E1462. 2016. View Article : Google Scholar
|
|
20
|
Cross DA, Ashton SE, Ghiorghiu S, Eberlein
C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ,
et al: AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated
resistance to EGFR inhibitors in lung cancer. Cancer Discov.
4:1046–1061. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pantel K, Diaz LA Jr and Polyak K:
Tracking tumor resistance using ‘liquid biopsies’. Nat Med.
19:676–677. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Imamura F, Uchida J, Kukita Y, Kumagai T,
Nishino K, Inoue T, Kimura M, Oba S and Kato K: Monitoring of
treatment responses and clonal evolution of tumor cells by
circulating tumor DNA of heterogeneous mutant EGFR genes in lung
cancer. Lung Cancer. 94:68–73. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chabon JJ, Simmons AD, Lovejoy AF,
Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr H, Scherer F,
Karlovich CA, et al: Circulating tumor DNA profiling reveals
heterogeneity of EGFR inhibitor resistance mechanisms in lung
cancer patients. Nat Commun. 7:118152016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chia PL, Do H, Morey A, Mitchell P,
Dobrovic A and John T: Temporal changes of EGFR mutations and T790M
levels in tumor and plasma DNA following AZD9291 treatment. Lung
Cancer. 98:29–32. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Uchida J, Imamura F, Kukita Y, Oba S,
Kumagai T, Nishino K, Inoue T, Kimura M and Kato K: Dynamics of
circulating tumor DNA represented by the activating and resistant
mutations in epidermal growth factor receptor tyrosine kinase
inhibitor treatment. Cancer Sci. 107:353–358. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Travis WD, Brambilla E, Burke AP, Marx A
and Nicholson AG: Introduction to the 2015 World Health
Organization Classification of tumors of the lung, Pleura, Thymus
and heart. J Thorac Oncol. 10:1240–1242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wu SG, Liu YN, Tsai MF, Chang YL, Yu CJ,
Yang PC, Yang JC, Wen YF and Shih JY: The mechanism of acquired
resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib
in lung adenocarcinoma patients. Oncotarget. 7:12404–12413. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Miller VA, Reuter V and Scher HI: Primary
squamous cell carcinoma of the prostate after radiation seed
implantation for adenocarcinoma. Urology. 46:111–113. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Devarakonda S, Morgensztern D and Govindan
R: Genomic alterations in lung adenocarcinoma. Lancet Oncol.
16:e342–e351. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yu JY, Yu SF, Wang SH, Bai H, Zhao J, An
TT, Duan JC and Wang J: Clinical outcomes of EGFR-TKI treatment and
genetic heterogeneity in lung adenocarcinoma patients with EGFR
mutations on exons 19 and 21. Chin J Cancer. 35:302016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hata A, Yoshioka H, Fujita S, Kunimasa K,
Kaji R, Imai Y, Tomii K, Iwasaku M, Nishiyama A, Ishida T and
Katakami N: Complex mutations in the epidermal growth factor
receptor gene in non-small cell lung cancer. J Thorac Oncol.
5:1524–1528. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Morgillo F, Corte CM Della, Fasano M and
Ciardiello F: Mechanisms of resistance to EGFR-targeted drugs: Lung
cancer. ESMO Open. 1:e0000602016. View Article : Google Scholar : PubMed/NCBI
|
